Published in J Neuropsychiatry Clin Neurosci on January 01, 2010
Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet (2011) 2.05
Mild cognitive impairment in prediagnosed Huntington disease. Neurology (2010) 1.96
Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep (2011) 1.55
The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest (2011) 1.11
Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci (2013) 1.10
Cognitive decline in prodromal Huntington Disease: implications for clinical trials. J Neurol Neurosurg Psychiatry (2013) 1.07
WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease. Eur J Hum Genet (2013) 1.07
Personal factors associated with reported benefits of Huntington disease family history or genetic testing. Genet Test Mol Biomarkers (2010) 1.06
Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD. PLoS Curr (2011) 0.96
Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch Clin Neuropsychol (2012) 0.90
Putting things into perspective: the nature and impact of theory of mind impairment in Huntington's disease. Eur Arch Psychiatry Clin Neurosci (2014) 0.86
Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J Psychiatr Res (2013) 0.86
Depression in the early stages of Huntington disease. Neurodegener Dis Manag (2011) 0.85
Executive functions in premanifest Huntington's disease. Mov Disord (2013) 0.84
Risk-taking and pathological gambling behavior in Huntington's disease. Front Behav Neurosci (2014) 0.84
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. Br J Clin Pharmacol (2015) 0.83
Perception, experience, and response to genetic discrimination in Huntington's disease: the Australian results of The International RESPOND-HD study. Genet Test Mol Biomarkers (2013) 0.83
Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease. Eur J Hum Genet (2015) 0.82
Longitudinal Change in Gait and Motor Function in Pre-manifest Huntington's Disease. PLoS Curr (2011) 0.81
Couples' coping in prodromal Huntington disease: a mixed methods study. J Genet Couns (2012) 0.81
Everyday cognition in prodromal Huntington disease. Neuropsychology (2014) 0.81
Movement sequencing in Huntington disease. World J Biol Psychiatry (2014) 0.80
Awareness of memory deficits in early stage Huntington's disease. PLoS One (2013) 0.80
New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Qual Life Res (2016) 0.80
Unawareness of motor phenoconversion in Huntington disease. Neurology (2013) 0.80
Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease. PLoS Curr (2011) 0.80
Perceived stress in prodromal Huntington disease. Psychol Health (2011) 0.80
Early Detection of Huntington Disease. Future Neurol (2010) 0.79
Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci (2016) 0.79
The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease. Neuropsychologia (2015) 0.79
Interaction without intent: the shape of the social world in Huntington's disease. Soc Cogn Affect Neurosci (2015) 0.78
Quantitative 7T phase imaging in premanifest Huntington disease. AJNR Am J Neuroradiol (2014) 0.77
Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review. J Huntingtons Dis (2014) 0.77
Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease. Neuropsychology (2015) 0.77
The many facets of unawareness in huntington disease. Tremor Other Hyperkinet Mov (N Y) (2014) 0.76
The Allure of High-Risk Rewards in Huntington's disease. J Int Neuropsychol Soc (2015) 0.75
Development of the Huntington disease work function scale. J Occup Environ Med (2012) 0.75
Abnormal Visual Scanning of Emotionally Evocative Natural Scenes in Huntington's Disease. Front Psychol (2017) 0.75
Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS One (2017) 0.75
Problem solving, impulse control and planning in patients with early- and late-stage Huntington's disease. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
Theory of mind and empathy in preclinical and clinical Huntington's disease. Soc Cogn Affect Neurosci (2015) 0.75
Striatal Neuropeptides Enhance Selection and Rejection of Sequential Actions. Front Comput Neurosci (2017) 0.75
Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures. Mov Disord (2017) 0.75
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord (1996) 8.02
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
Structural MR image processing using the BRAINS2 toolbox. Comput Med Imaging Graph (2002) 4.19
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol (2001) 2.52
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain (2008) 2.40
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol (2004) 2.10
Brain structure in preclinical Huntington's disease. Biol Psychiatry (2005) 2.05
Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry (2001) 2.04
Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain (1998) 1.84
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol (1996) 1.74
Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology (1997) 1.56
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry (2003) 1.49
Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol (2007) 1.47
Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol (1999) 1.41
Frontal lobe volume in patients with Huntington's disease. Neurology (1998) 1.38
White matter volume and cognitive dysfunction in early Huntington's disease. Cogn Behav Neurol (2005) 1.34
Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci (2005) 1.34
Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry (2007) 1.32
Factor analysis of the frontal systems behavior scale (FrSBe). Assessment (2003) 1.27
Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry (2008) 1.17
Awareness of involuntary movements in Huntington disease. Arch Neurol (1998) 1.16
Effects of depression on working memory in presymptomatic Huntington's disease. J Neuropsychiatry Clin Neurosci (2001) 1.14
Frontal-subcortical dementias. Neurologist (2008) 1.14
Behavior in Huntington's disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci (2002) 1.13
Probability of obsessive and compulsive symptoms in Huntington's disease. Biol Psychiatry (2006) 1.12
Risky decision making in Huntington's disease. J Int Neuropsychol Soc (2001) 1.08
Cognitive procedural learning in patients with fronto-striatal lesions. Learn Mem (2002) 1.00
Evidence of a neurologically based "denial of illness" in patients with Huntington's disease. Arch Clin Neuropsychol (1996) 0.97
A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci (2005) 0.96
Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum Brain Mapp (2009) 0.94
Cognitive impairment related to apathy in early Huntington's disease. Dement Geriatr Cogn Disord (2006) 0.88
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol (2005) 3.89
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol (2013) 3.56
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci U S A (2002) 3.34
p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron (2005) 3.13
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol (2011) 2.99
Abnormal functional connectivity in autism spectrum disorders during face processing. Brain (2008) 2.75
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry (2002) 2.52
Reduced neural habituation in the amygdala and social impairments in autism spectrum disorders. Am J Psychiatry (2009) 2.45
Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry (2002) 2.41
A contribution of cognitive decision models to clinical assessment: decomposing performance on the Bechara gambling task. Psychol Assess (2002) 2.32
Abnormal brain structure in children with isolated clefts of the lip or palate. Arch Pediatr Adolesc Med (2007) 2.29
Using cognitive models to map relations between neuropsychological disorders and human decision-making deficits. Psychol Sci (2005) 2.25
Defining the broader phenotype of autism: genetic, brain, and behavioral perspectives. Dev Psychopathol (2002) 2.21
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Neurocognitive signs in prodromal Huntington disease. Neuropsychology (2011) 2.14
Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem (2002) 2.12
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry (2010) 2.11
fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol (2004) 2.10
Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet (2011) 2.05
Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol (2008) 2.03
Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ (2009) 2.02
Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology (2010) 1.98
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet (2005) 1.92
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet (2003) 1.85
Coercion and informed consent in research involving prisoners. Compr Psychiatry (2003) 1.84
Neurocognitive insights into substance abuse. Trends Cogn Sci (2005) 1.82
Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull (2010) 1.79
Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. Arch Clin Neuropsychol (2006) 1.77
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord (2009) 1.73
Cognition assessment using the NIH Toolbox. Neurology (2013) 1.73
An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord (2011) 1.68
Challenges assessing clinical endpoints in early Huntington disease. Mov Disord (2010) 1.66
Short-term practice effects in amnestic mild cognitive impairment: implications for diagnosis and treatment. Int Psychogeriatr (2008) 1.64
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A (2009) 1.64
A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. J Med Genet (2012) 1.63
Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet (2005) 1.62
I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data. Monogr Soc Res Child Dev (2013) 1.61
Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol (2007) 1.61
Measures of growth in children at risk for Huntington disease. Neurology (2012) 1.59
Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem (2008) 1.56
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry (2010) 1.53
Fully automated analysis using BRAINS: AutoWorkup. Neuroimage (2010) 1.52
Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res (2012) 1.50
Predictors of diagnosis in Huntington disease. Neurology (2007) 1.48
Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem (2009) 1.47
Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol (2007) 1.47
FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2005) 1.46
The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry (2003) 1.46
Earliest functional declines in Huntington disease. Psychiatry Res (2010) 1.45
A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci (2004) 1.45
Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res (2005) 1.43